TrialLancet (London, England)2015

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Bryan Williams et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.